The AACE/ACE, in contrast to the ADA, provides several monotherapy options that are recommended in the following order according to the strength of each recommendation: metformin, GLP-1 receptor agonist, SGLT-2 inhibitor, DPP-4 inhibitor, thiazolidinedione, -glucosidase inhibitor, and an insulin secretagogue (a sulfonylurea or meglitinide)
Pyke C, Knudsen LB (2013) The Glucagon-Like Peptide-1 Receptoror Not
Similarly, it is now possible to perform spatially-differentiated multi-omic tissue profiling, such that the content of DNA, production of transcripts, and expression of proteins thus discovered can be differentiated according to precise cellular, or even sub-cellular, origin
Similar effects of mutations were observed with the binding of teduglutide (Table 1)